Magro DO, Cazzo E, Kotze PG, Vasques ACJ, Martinez CAR, Chaim EA, et al
Some research community protocols combine 5-Amino-1MQ with AOD-9604 (fat oxidation) or with a GLP-1 drug like semaglutide (appetite suppression), since the mechanisms do not overlap
These analyses suggest that the study by Vignera (2023) [12] was primarily responsible for the observed heterogeneity
The information on this page is based on the average treatment experience
Adults apply two-to-three pumps over the liver or on a thin skin area without hair, or as directed by your healthcare practitioner
(21CFR312.32) Safety reporting Adverse events (annual) Serious Adverse Events (SAEs) (within 7 days) Serious Adverse Reactions (SARs) (within 7 days) Suspected Unexpected Serious Adverse Reactions (SUSARs) (expedited) Expedited reporting Fatal or life threatening SUSARS:not later than 7 days after the person responsible for pharmacovigilance received information that the case fulfilled the criteria for a fatal or life threatening SUSAR, and any follow up information within a further 8 days
